Cited by

• Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

  Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. Mastellos DC, et al. Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Semin Hematol. 2018. PMID: 30032754 Free PMC article. Review.
• Long noncoding RNA FAM157C contributes to clonal proliferation in paroxysmal nocturnal hemoglobinuria.

  Wang H, Liu H, Li L, Chen Y, Liu Z, Li L, Ding S, Ding K, Fu R. Wang H, et al. Ann Hematol. 2023 Feb;102(2):299-309. doi: 10.1007/s00277-022-05055-8. Epub 2023 Jan 6. Ann Hematol. 2023. PMID: 36607351 Free PMC article.
• Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.

  Hatanaka M, Seya T, Matsumoto M, Hara T, Nonaka M, Inoue N, Takeda J, Shimizu A. Hatanaka M, et al. Biochem J. 1996 Mar 15;314 ( Pt 3)(Pt 3):969-76. doi: 10.1042/bj3140969. Biochem J. 1996. PMID: 8615796 Free PMC article.
• The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis.

  Shah YB, Priore SF, Li Y, Tang CN, Nicholas P, Kurre P, Olson TS, Babushok DV. Shah YB, et al. Blood Adv. 2021 Aug 24;5(16):3216-3226. doi: 10.1182/bloodadvances.2021004201. Blood Adv. 2021. PMID: 34427585 Free PMC article.
• Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation.

  Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Sugimori C, et al. Blood Cancer J. 2012 Mar;2(3):e63. doi: 10.1038/bcj.2012.7. Epub 2012 Mar 23. Blood Cancer J. 2012. PMID: 22829258 Free PMC article. No abstract available.